Wang W - Search Results

1

Cross-neutralizing antibodies to pandemic 2009 H1N1 and recent seasonal H1N1 influenza A strains influenced by a mutation in hemagglutinin subunit 2.

Wang W, Anderson CM, De Feo CJ, Zhuang M, Yang H, Vassell R, Xie H, Ye Z, Scott D, Weiss CD. Wang W, et al. PLoS Pathog. 2011 Jun;7(6):e1002081. doi: 10.1371/journal.ppat.1002081. Epub 2011 Jun 9. PLoS Pathog. 2011. PMID: 21695241 Free PMC article.

2

Establishment of retroviral pseudotypes with influenza hemagglutinins from H1, H3, and H5 subtypes for sensitive and specific detection of neutralizing antibodies.

Wang W, Butler EN, Veguilla V, Vassell R, Thomas JT, Moos M Jr, Ye Z, Hancock K, Weiss CD. Wang W, et al. J Virol Methods. 2008 Nov;153(2):111-9. doi: 10.1016/j.jviromet.2008.07.015. Epub 2008 Sep 4. J Virol Methods. 2008. PMID: 18722473

3

Characterization of lentiviral pseudotypes with influenza H5N1 hemagglutinin and their performance in neutralization assays.

Wang W, Xie H, Ye Z, Vassell R, Weiss CD. Wang W, et al. J Virol Methods. 2010 May;165(2):305-10. doi: 10.1016/j.jviromet.2010.02.009. Epub 2010 Feb 11. J Virol Methods. 2010. PMID: 20153374

4

Nanoparticle-based biosensor for the detection of emerging pandemic influenza strains.

Kamikawa TL, Mikolajczyk MG, Kennedy M, Zhang P, Wang W, Scott DE, Alocilja EC. Kamikawa TL, et al. Among authors: wang w. Biosens Bioelectron. 2010 Dec 15;26(4):1346-52. doi: 10.1016/j.bios.2010.07.047. Epub 2010 Jul 21. Biosens Bioelectron. 2010. PMID: 20729069

5

A mutation in the receptor binding site enhances infectivity of 2009 H1N1 influenza hemagglutinin pseudotypes without changing antigenicity.

Wang W, Castelán-Vega JA, Jiménez-Alberto A, Vassell R, Ye Z, Weiss CD. Wang W, et al. Virology. 2010 Nov 25;407(2):374-80. doi: 10.1016/j.virol.2010.08.027. Epub 2010 Sep 24. Virology. 2010. PMID: 20869738 Free article.

6

Selection with a peptide fusion inhibitor corresponding to the first heptad repeat of HIV-1 gp41 identifies two genetic pathways conferring cross-resistance to peptide fusion inhibitors corresponding to the first and second heptad repeats (HR1 and HR2) of gp41.

Wang W, De Feo CJ, Zhuang M, Vassell R, Weiss CD. Wang W, et al. J Virol. 2011 Dec;85(24):12929-38. doi: 10.1128/JVI.05391-11. Epub 2011 Oct 12. J Virol. 2011. PMID: 21994458 Free PMC article.

7

Comparison of hemagglutination inhibition and hemagglutinin pseudovirus neutralization titres in relation to protection against influenza in a mouse model.

Huang Y, Lin Z, Wang W, Weiss C, Xie H, Forshee RA. Huang Y, et al. Among authors: wang w. Lett Appl Microbiol. 2021 Sep;73(3):294-299. doi: 10.1111/lam.13513. Epub 2021 Jun 11. Lett Appl Microbiol. 2021. PMID: 34028058

8

SARS-CoV-2 Omicron neutralization by therapeutic antibodies, convalescent sera, and post-mRNA vaccine booster.

Lusvarghi S, Pollett SD, Neerukonda SN, Wang W, Wang R, Vassell R, Epsi NJ, Fries AC, Agan BK, Lindholm DA, Colombo CJ, Mody R, Ewers EC, Lalani T, Ganesan A, Goguet E, Hollis-Perry M, Coggins SA, Simons MP, Katzelnick LC, Wang G, Tribble DR, Bentley L, Eakin AE, Broder CC, Erlandson KJ, Laing ED, Burgess TH, Mitre E, Weiss CD. Lusvarghi S, et al. Among authors: wang w, wang g, wang r. bioRxiv [Preprint]. 2021 Dec 28:2021.12.22.473880. doi: 10.1101/2021.12.22.473880. bioRxiv. 2021. Update in: Sci Transl Med. 2022 May 18;14(645):eabn8543. doi: 10.1126/scitranslmed.abn8543 PMID: 34981057 Free PMC article. Updated. Preprint.

9

SARS-CoV-2 BA.1 variant is neutralized by vaccine booster-elicited serum but evades most convalescent serum and therapeutic antibodies.

Lusvarghi S, Pollett SD, Neerukonda SN, Wang W, Wang R, Vassell R, Epsi NJ, Fries AC, Agan BK, Lindholm DA, Colombo CJ, Mody R, Ewers EC, Lalani T, Ganesan A, Goguet E, Hollis-Perry M, Coggins SA, Simons MP, Katzelnick LC, Wang G, Tribble DR, Bentley L, Eakin AE, Broder CC, Erlandson KJ, Laing ED, Burgess TH, Mitre E, Weiss CD. Lusvarghi S, et al. Among authors: wang w, wang g, wang r. Sci Transl Med. 2022 May 18;14(645):eabn8543. doi: 10.1126/scitranslmed.abn8543. Epub 2022 May 18. Sci Transl Med. 2022. PMID: 35380448 Free PMC article.

10

Characterization of Entry Pathways, Species-Specific Angiotensin-Converting Enzyme 2 Residues Determining Entry, and Antibody Neutralization Evasion of Omicron BA.1, BA.1.1, BA.2, and BA.3 Variants.

Neerukonda SN, Wang R, Vassell R, Baha H, Lusvarghi S, Liu S, Wang T, Weiss CD, Wang W. Neerukonda SN, et al. Among authors: wang w, wang t, wang r. J Virol. 2022 Sep 14;96(17):e0114022. doi: 10.1128/jvi.01140-22. Epub 2022 Aug 24. J Virol. 2022. PMID: 36000843 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

88,080 results

Search Page

Filters